PAVmed’s digital health subsidiary Veris Health has announced the commercial roll out of its Veris Cancer Care Platform (Veris CCP).

The new digital cancer care platform has been designed for improving personalised cancer care through remote patient monitoring.

It includes symptom reporting, telehealth functions, and physiologic data collection.

Cancer patients who are enrolled in the Veris CCP programme will receive a VerisBox that includes Veris-branded Bluetooth enabled connected health care devices.

Through the Veris CCP patient smartphone app and Cloud-based Veris CCP clinician portal, the health care devices transmit patient’s clinical data to the cancer care team.

With the Veris CCP platform, the care team will be able to identify early signs of common cancer-related problems.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

It also provides data-driven risk management tools, along with longitudinal physiologic and clinical data trends for precision oncology.

The practice makes use of remote patient monitoring (RPM) codes to review and interpret the clinical data.

Veris executive chairman and PAVmed chairman and CEO Lishan Aklog said: “We are excited to offer oncology practices and their patients a state-of-the-art cancer-focused digital health platform designed to enhance care and improve outcomes through remote patient monitoring (RPM).

“Our software-as-a-service recurring-revenue business model leverages well-established RPM codes and provides attractive margins to Veris and its clients.

“We look forward to further enhancing the power of the platform next year, with the anticipated launch of our implantable physiological monitor designed to be implanted in conjunction with a vascular access port for chemotherapy.”

Additionally, the company has executed its first commercial contract with oncology services provider, New Jersey Cancer Care (NJCC).